Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

232
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
232
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of the Efficacy of Different Treatment Regimens for Resistant Hypertension: A Systematic Review and Network Meta-Analysis.

Journal of evidence-based medicineĀ·2026
Same author

Population pharmacokinetic-pharmacodynamic analysis and dose optimisation of ciprofol in paediatric anaesthesia.

British journal of anaesthesiaĀ·2026
Same author

Preparation and Bioactivity Evaluation of Novel Dihydrotanshinone I Derivatives via Biotransformation by <i>Ganoderma lingzhi</i>.

Journal of fungi (Basel, Switzerland)Ā·2026
Same author

A Pheromone-Dominant Odorant-Binding Protein Mediates Mating and Host Volatile Perception in <i>Anomala corpulenta</i>.

Journal of agricultural and food chemistryĀ·2026
Same author

pH-responsive in situ hydrogelation behavior of a dipotassium glycyrrhizinate-propylene glycol alginate micro-hydrogel for oral sustained release of kaempferol.

Colloids and surfaces. B, BiointerfacesĀ·2026
Same author

PSMC2 drives tumor progression in nasopharyngeal carcinoma by inhibiting ferroptosis through STAT3.

Discover oncologyĀ·2026

Related Experiment Video

Updated: Aug 10, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K

EGCG adjuvant chemotherapy: Current status and future perspectives.

Lin Wang1, Penghui Li2, Kun Feng1

  • 1Pingshan District People's Hospital of Shenzhen, Pingshan General Hospital of Southern Medical University, Shenzhen, 518118, Guangdong, China.

European Journal of Medicinal Chemistry
|February 13, 2023
PubMed
Summary

Epigallocatechin-3-gallate (EGCG), a tea compound, enhances chemotherapy effectiveness and reduces side effects. Nanomodification of EGCG improves its delivery and antitumor activity, showing promise for cancer treatment.

Keywords:
Cancer therapyChemotherapyEpigallocatechin-3-gallateNanomaterialsSide effects

More Related Videos

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.3K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Related Experiment Videos

Last Updated: Aug 10, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.3K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Natural Products Chemistry

Background:

  • Cancer cell resistance to chemotherapy limits treatment efficacy and patient quality of life.
  • Chemotherapy often causes severe adverse effects, including gastrointestinal, renal, and cardiac toxicities.
  • Epigallocatechin-3-gallate (EGCG), a tea polyphenol, exhibits potential anticancer properties.

Purpose of the Study:

  • To review the current status and challenges of using EGCG in combination with chemotherapy for cancer treatment.
  • To explore the mechanisms by which EGCG enhances chemotherapy efficacy and mitigates side effects.
  • To discuss the potential of nanomodified EGCG in improving cancer therapy.

Main Methods:

  • Literature review of studies investigating EGCG in combination with chemotherapeutic agents (cisplatin, 5-FU, doxorubicin, paclitaxel).
  • Analysis of mechanisms including overcoming cancer stem cell drug resistance, enhancing drug sensitivity, inducing apoptosis, and blocking angiogenesis.
  • Evaluation of EGCG's anti-inflammatory and antioxidant effects on chemotherapy-induced toxicities.
  • Assessment of nanomodification strategies for EGCG and chemotherapeutic drugs.

Main Results:

  • EGCG enhances the efficacy of various chemotherapy drugs and combats cancer cell drug resistance.
  • EGCG demonstrates potential in overcoming drug resistance mediated by cancer stem cells.
  • EGCG exhibits anti-inflammatory and antioxidant properties, mitigating chemotherapy-induced side effects and improving patient quality of life.
  • Nanomodification of EGCG and chemotherapy drugs enhances antitumor activity and prolongs survival in preclinical models with reduced toxicity.

Conclusions:

  • EGCG is a promising adjuvant for chemotherapy, enhancing efficacy and reducing toxicity.
  • Challenges such as low bioavailability and off-target effects of EGCG require further investigation and solutions like nanomodification.
  • Further research and clinical trials are warranted to fully realize the therapeutic potential of EGCG in cancer treatment.